Biocryst Pharmaceuticals Inc.’s near-term dilution should “pave the way for entrenchment” in the hereditary angioedema (HAE) space, thanks to the buyout of Astria Therapeutics Inc., RBC analyst Brian Abrahams said. Read More
Two biopharma companies launched within the past year raised top amounts in series B financings for 2025, seeking to advance their therapeutic candidates for cardiovascular diseases and obesity. Read More
Astellas Pharma Inc. reported Oct. 14 that its CLDN18.2-targeting monoclonal antibody, zolbetuximab (Vyloy), did not meet the primary endpoint of overall survival in the phase II Gleam trial of patients with advanced pancreatic cancer. Read More
The importance of scalability, combination therapies, immunotherapies and speed in developing cancer drugs are paramount in creating a revolution in treating patients who often don’t have much hope, according to a panel of developers who spoke at the BioFuture conference in New York. Read More
John Squires, the recently anointed director of the U.S. Patent and Trademark Office, has determined that a machine learning patent application met the standard for patent subject matter eligibility, an outcome that seems to bode well for ML-based patent applications going forward. Read More
BioWorld Staff Writer Tamra Sami says it’s impossible to talk about changes to the biotech and med-tech landscape in Asia without discussing China, which is eclipsing the region. In the last two decades, China has shifted from imitator to innovator. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Avidity, Beone, Bicara, Lundbeck, Mannkind, Medincell, Revir, Teva. Read More
